Home > Publications database > Refining the role of N6-methyladenosine in cancer. > print

001     292119
005     20250815134749.0
024 7 _ |a 10.1016/j.gde.2024.102242
|2 doi
024 7 _ |a pmid:39111230
|2 pmid
024 7 _ |a 0959-437X
|2 ISSN
024 7 _ |a 1879-0380
|2 ISSN
037 _ _ |a DKFZ-2024-01618
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Koch, Jonas
|0 P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea
|b 0
|e First author
|u dkfz
245 _ _ |a Refining the role of N6-methyladenosine in cancer.
260 _ _ |a Amsterdam
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723122835_32133
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A130#LA:A130# / DKFZ-ZMBH Alliance
520 _ _ |a N6-methyladenosine (m6A) is the most abundant internal modification of eukaryotic mRNAs. m6A affects the fate of its targets in all aspects of the mRNA life cycle and has important roles in various physiological and pathophysiological processes. Aberrant m6A patterns have been observed in numerous cancers and appear closely linked to oncogenic phenotypes. However, most studies relied on antibody-dependent modification detection, which is known to suffer from important limitations. Novel, antibody-independent, quantitative approaches will be critical to investigate changes in the m6A landscape of cancers. Furthermore, pharmaceutical targeting of the m6A writer Methyltransferase-like 3 (METTL3) has demonstrated the potential to modulate cancer cell phenotypes. However, the enzyme also appears to be essential for the viability of healthy cells. Further refinement of therapeutic strategies is therefore needed to fully realize the potential of m6A-related cancer therapies.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Lyko, Frank
|0 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.gde.2024.102242
|g Vol. 88, p. 102242 -
|0 PERI:(DE-600)2013031-4
|p 102242
|t Current opinion in genetics & development
|v 88
|y 2024
|x 0959-437X
856 4 _ |u https://inrepo02.dkfz.de/record/292119/files/1-s2.0-S0959437X24000911-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292119/files/1-s2.0-S0959437X24000911-main.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:292119
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CURR OPIN GENET DEV : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-22
920 2 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
920 0 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
920 1 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A130-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21